In order to assess long-term safety of radioactive iodine administration in treatment of thyrotoxicosis, we assessed concentrations of selected markers of risk cardiovascular disease, i.e. matrix metalloproteinase 2 (MMP-2), its main inhibitor TIMP-2, matrix metalloproteinase 9 (MMP-9), its main inhibitor TIMP-1, as well concentrations of anti-inflammatory adiponectin and pro-inflammatory thrombospondin.
Introduction
In order to assess long-term safety of radioactive iodine administration in treatment of thyrotoxicosis, we assessed concentrations of selected markers of risk cardiovascular disease, i.e. matrix metalloproteinase 2 (MMP-2), its main inhibitor TIMP-2, matrix metalloproteinase 9 (MMP-9), its main inhibitor TIMP-1, as well concentrations of anti-inflammatory adiponectin and pro-inflammatory thrombospondin.
Material and methods
The study involved 23 patients (3 males) age 53±12 (mean ±SD) years treated with radioiodine for thyrotoxicosis. Serum concentrations TSH, fT4, fT3, MMP-2, MMP-9, TIMP-1, TIMP-2, adiponectin and thrombospondin were measured just before radioiodine administration (visit 1), and subsequently, after 7 days (visit 2), 3 months (visit 3), six to eight months (visit 4) and 15-18 months after radioiodine administration (visit 5).
Results
There were no acute changes in serum concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 adiponectin and thrombospondin (visit 1 versus visit 2). Subsequently, however, there was no change in serum MMP-9 or thrombospondin, but an increase in MMP-2 (from 393±106 ng/ml, to 774 ± 424 ng/ml), TIMP-1 (from 177 ± 76 ng/ml to 296 ± 118 ng/ml), TIMP-2 (from 136 ± 44 ng/ml to 168 ± 41 ng/ml), and adiponectin (from 16442±9490 ng/ml to 23518 ± 9840 ng/ml), visit 1 to visit 5 respectively, p<0.01). Further analysis, however, revealed no significant change in MMP-2/TIMP-2 ratio, but there was a significant decrease in MMP-9/TIMP-1 ratio (p<0.05), suggestive of possible decrease in concentrations of free MMP-9.
Conclusions
Our data reveal a significant and sustained increase in serum adiponectin as well as possible decrease of concentration of free MMP-9 after radioiodine administration. This might indicate overall safety of radioiodine treatment of thyrotoxicosis in terms of the risks of cardiovascular disease.
